Content :

The Group's profile

A diversified global healthcare leader, discovers, develops and delivers healthcare solutions focused on patients’ needs

• Zoom: A diversified global healthcare leader, discovers, develops and delivers healthcare solutions focused on patients’ needs

Sanofi Key Activities

Our business includes three main activities: Pharmaceuticals, Human Vaccines through Sanofi Pasteur and Animal Health products through Merial Limited (Merial).

For more information:

• Annual Report on Form F-20 2011 (PDF, 1289Kb)

Pharmaceuticals

• 2011 net sales of the pharmaceuticals business: €27,890 million, +6.7% at Constant Exchange Rate (CER)

Sanofi's pharmaceuticals business notably focuses on diabetes, oncology, and other flagship products in thrombosis, cardiovascular, central nervous system, internal medicine areas. Since April 1st 2011, Sanofi’s pharmaceuticals business also includes Genzyme products.

Sanofi also has a significant presence in Consumer Health Care, in various product categories.

• 2011 net sales of Consumer Health Care: €2,666 million, +22.8% at CER

In addition, our pharmaceuticals portfolio comprises other prescription drugs including Generics.

• 2011 net sales of Generics: €1,746 million, +16.2% at CER

For more information:

• en.sanofi.com / Investors / Key facts and figures

Human Vaccines

• 2011 net sales of the vaccines business: €3,469 million, - 5.5% at CER, +7.2% excluding A/H1N1 vaccines sales.

Sanofi Pasteur, the fully integrated vaccines business of Sanofi, is a world leader in the vaccines industry offering a large range of vaccines covering 20 different infectious diseases.

For more information:

• en.sanofi.com / Investors / Key facts and figures

Animal Health

• 2011 sales of Merial: €2,030 million, +4.3% at CER

Merial, a wholly owned subsidiary of Sanofi since September 18, 2009, is one of the world’s leading animal health companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners.

For more information:

• en.sanofi.com / Investors / Key facts and figures

Geographic Presence

Sanofi has commercial presence in more than 100 countries, and our products are available in more than 170 countries.

For more information:

• en.sanofi.com / Investors / Key facts and figures

Sanofi is the established leader in pharmaceuticals in Emerging Markets, holding top positions in the main countries. In 2011, Emerging Markets totaled €10,133 million, an increase of 10.4% (excluding Genzyme and A/H1N1 vaccines sales of €361 million booked in 2010). Emerging Markets sales contribute to 30.3% of the Group sales and become the most important contributors to the region sales. In 2011, Emerging Markets sales recorded double digit growth (up 12.4% to €507 million) accounting for 25.0% of total Merial sales.

Sanofi accross the world

By geographical areas

By Presence / Activity type